Articles from TwoStep Therapeutics

TwoStep Therapeutics, a biotechnology company developing innovative, first-in-class, multispecific targeted peptide conjugate therapies for solid tumors, will be presenting a poster at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting, being held November 7–9, 2025, at the Gaylord National Resort and Convention Center in National Harbor, MD.

TwoStep Therapeutics, a biotechnology company developing innovative, first-in-class, multispecific targeted peptide conjugate therapies for solid tumors, will be presenting at the 2025 PEGS Boston Summit taking place in Boston, Massachusetts on May 13, 2025.

TwoStep Therapeutics (“TwoStep”), a biotechnology company developing innovative, first in class, multispecific targeted peptide conjugate therapies for solid tumors, is pleased to announce that it was selected to join Johnson & Johnson’s global incubator network, JLABS, as a resident at the MBC BioLabs site. TwoStep is a Stanford University spin-out launched in 2024, co-founded by Nobel Prize winner Carolyn Bertozzi, Jennifer Cochran, Ron Levy, and Caitlyn Miller, with seed investment of $8.7M to date led by NFX.

TwoStep Therapeutics, a biotechnology company developing innovative, first-in-class, multispecific targeted peptide conjugate therapies for solid tumors, is pleased to announce its debut public scientific presentation on March 27, 2025, at the 4th Novel Conjugates Summit taking place in Boston, Massachusetts. This presentation will highlight the outstanding preclinical efficacy and safety of its lead tumor-targeted drug conjugate program, along with a first look at their new radiopharmaceutical program.

TwoStep Therapeutics, a biotechnology company developing new targeted therapeutics for solid tumors, today announced its official launch following a successful $6.5 million seed round led by NFX, with participation from other investors including 2048 Ventures, Alexandria Venture Investments, Cooley’s affiliated fund GC&H Investments, and the family office of the founder of Arcadia Investment Partners. Proceeds from the financing will be used to advance TwoStep’s therapeutic pipeline of solid tumor-targeting therapies, with an initial focus on targeted cytotoxic drug delivery and immunotherapy.